Skip to content
    Schroders Capital logo

    Schroders Capital

    London, United KingdomFounded 1997

    Schroders Capital's venture capital investment focus is on selective early-stage opportunities, aiming to capture distributed innovation across diverse global regions and ecosystems. Their strategy involves backing top-tier managers, diversifying across managers, geographies, and sectors, and emphasizing operational value-add.

    Deal activity increased 33% year-over-year (8 deals in the last 12 months). Average disclosed round size is $196.6M (across 22 rounds with reported amounts).

    Find people at Schroders Capital on Goldilocks AI

    Portfolio

    22

    Fund Size

    $99.3B

    Top Stage

    Series B

    Last 12 Mo

    8

    Team

    Nils Rode

    Nils Rode

    Co-Founder & General Partner

    GW

    Georg Wunderlin

    Chief Executive Officer

    MP

    Minal Patel

    Global Head of Infrastructure

    RE

    Rainer Ender

    Global Head of Private Equity

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    22 investments
    CompanyRoundAmountDate
    Kainova Therapeutics logoKainova TherapeuticsSeries B$32MFeb 2026
    Tem logoTemSeries B$75MFeb 2026
    Tem logoTemSeries C$75MFeb 2026
    Kinaset Therapeutics logoKinaset TherapeuticsSeries B$103MJan 2026
    MoEngage logoMoEngageSeries F$180MDec 2025
    Artios Pharma Limited logoArtios Pharma LimitedSeries D$115MNov 2025
    AAAVantgarde BioSeries B$141MNov 2025
    Vercel logoVercelGrowth$300MSep 2025
    Cyberhaven logoCyberhavenSeries D$100MApr 2025
    Luminance logoLuminanceSeries C$75MFeb 2025
    Cera logoCeraGrowth$150MJan 2025
    Poolside logoPoolsideSeries B$500MOct 2024
    EEnfinity Global Inc.Unknown$500MAug 2024
    iOnctura logoiOncturaSeries B$80MJun 2024
    Cohere logoCohereSeries C$270MJun 2023
    Cera Care logoCera CareGrowth$310MAug 2022
    Cera logoCeraGrowth$320MAug 2022
    Eikon Therapeutics logoEikon TherapeuticsSeries B$517.8MJan 2022
    Artios Pharma Limited logoArtios Pharma LimitedSeries C$153MJul 2021
    Graphcore logoGraphcoreSeries E$222MDec 2020
    Antler logoAntlerSeries C$75MFeb 2020
    Nutmeg logoNutmegSeries B$32MJun 2014

    Top Co-Investors

    Stepstone4 shared
    M Ventures3 shared
    Allianz2 shared
    AlbionVC2 shared
    Atomico2 shared
    Revent2 shared
    Adams Street2 shared
    Nvidia2 shared
    Yabeo2 shared

    Last updated: 15 April 2026